Netherton Syndrome Market Report and Forecast 2024-2032

Netherton Syndrome Market Report and Forecast 2024-2032

Netherton Syndrome Market Report and Forecast 2024-2032

Netherton Syndrome Market Size

The Netherton syndrome market is expected to grow at a CAGR of 11.8% during the forecast period of 2024-2032, driven by rising healthcare expenditure on research initiatives and surge in merger and acquisitions across the 8 major markets.

Netherton Syndrome Market Outlook

• Netherton syndrome is an autosomal recessive skin disease, affecting 1 to 9 people per million in the population.
• One of the major market trends is the surge in clinical trials of new and advanced medications, which are projected to enhance patient outcomes and stimulate market expansion in the forecast period.
• United States is expected to lead the market share driven by the presence of prominent healthcare companies and academic institutions which are dedicated towards developing effective solutions to manage the condition.

Netherton Syndrome Market Overview

Netherton syndrome (also known as bamboo hair syndrome, Comel-Netherton syndrome or ichthyosis erythroderma) is a skin disorder characterized by chronic inflammation, persistent itching, hair thinning, along with the presence of circular, scaly rashes on the skin. With its multisystemic nature, the condition goes beyond affecting skin and may also cause sleep disorders, recurrent infections, immune system associated problems like rhinitis and conjunctivitis among others.

Netherton syndrome is caused by a mutation in the SPINK5 gene and affects 1 to 9 individuals per million in the global population. Since its symptoms coincide with other common indications, the diagnosis can be difficult. The mortality rate associated with the condition can range between 10%-20%. The market is driven by an emphasis on developing effective diagnostic methods for the condition, along with treatment solutions to specifically manage the condition in newborns.

Netherton Syndrome Market Growth Drivers

Rise in the Development of Innovative Therapies to Meet Rising Market Demand

In March 2024, an Israel-based pharmaceutical company focused on rare and orphan diseases Quoin Pharmaceuticals Ltd. received United States FDA clearance to recruit teens in the 2 ongoing clinical trials for QRX003 (a topical lotion to treat Netherton Syndrome). The designation of non-adult Netherton subjects is intended to address a wider pool of patients and represents the first time that non-adult Netherton participants will be tested in clinical studies. This highlights the increasing focus of the pharmaceutical sector on developing viable treatment options for rare diseases, which is expected to drive market growth. Additionally, improvements in regulatory framework, rising focus on rare disease research, and increasing advancements in gene therapy are some of the factors that are poised to stimulate the market in the coming years.

Netherton Syndrome Market Trends

Growth in Clinical Trials is Expected to Support Market Expansion

In May 2024 , a clinical-stage biopharmaceutical company Azitra Inc., presented robust preclinical data on its candidate for Netherton syndrome, ATR-12, at ASGCT (American Society of Gene and Cell Therapy) Baltimore. It was revealed that the topical application of ATR-12 to ex vivo human skin shows the potential for superior LEKTI delivery as compared to topical LEKTI application. The preclinical data also demonstrated that the drug candidate reduced the pro-inflammatory cytokine IL-36γ that drives Netherton syndrome by 93%, thus supporting the rationale behind their Phase 1b clinical trial in Netherton syndrome patients. The rising number of such clinical trials to develop effective therapies for this rare genetic disorder is expected to accelerate market growth.

Strategic Partnerships Poised to Boost the Market Share

One of the major market trends is the rise in strategic partnerships among the key market players to expedite the introduction of promising treatment therapies in healthcare settings for Netherton syndrome patients. In July 2022 , it was reported that Endo International plc’s subsidiary Endo Ventures Limited signed an agreement with specialty pharmaceutical company Quoin Pharmaceuticals Inc. to develop, register, supply, commercialize, and facilitate distribution of Quoin's lead product for Netherton syndrome, QRX003, on an exclusive basis in Canada. Once it receives market approval, Paladin Labs Inc., an operating company of Endo, will handle all the commercial activities for the drug candidate in Canada. Such collaborative initiatives are projected to amplify market demand by catalyzing the development and commercialization of therapeutic products that treat this rare disease.

Growing Investments in Rare Disease Research is Likely to Elevate Netherton Syndrome Market Value

Pharmaceutical companies and research institutions are showing increasing interest in rare diseases like Netherton Syndrome, leading to more funding and research aimed at finding effective treatments. Recent research indicates that investments in developing rare disease therapies have increased in terms of dollar value and new drug candidates, influencing the market value. These rising funding initiatives can be attributed to extended exclusivity periods, accelerated clinical development, and incentives for pediatric drug development , among others.

Increasing Awareness and Diagnosis Rates Impact Netherton Syndrome Market Demand

The market is witnessing an increasing awareness among the public as well as healthcare providers regarding rare diseases, including Netherton Syndrome, which is resulting in higher diagnosis rates. Early diagnosis increases the demand for treatment therapies and is also crucial for managing the condition effectively. Further, the rising improvements in diagnostic technologies, including next-generation sequencing and skin biopsy analyses, are facilitating accurate and faster diagnosis of Netherton Syndrome.

Netherton Syndrome Market Segmentation

Market Breakup by Therapy

• Keratolytic Agents
• Oral and Topical Steroids and Retinoid
• Topical Calcineurin Inhibitors
• Radiation Therapies
• Biological Therapies
• Others

Market Breakup by Route of Administration

• Oral
• Parenteral
• Topical
• Others

Market Breakup by Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

Market Breakup by Region

• United States
• EU-4 and the United Kingdom
• Germany
• France
• Italy
• Spain
• United Kingdom
• Japan
• India

Netherton Syndrome Market Share

Therapy Based Market Segmentation Projected to Witness Substantial Growth

Based on therapy, the market segmentation encompasses keratolytic agents, oral and topical steroids and retinoids, topical calcineurin inhibitors, radiation therapies, and biological therapies among others. Keratolytic agents are used to treat scaling and hyperkeratosis associated with the condition. These agents exfoliate the skin by removing the outer layer. Orals, topical steroids, and retinoids hold a significant market share as they help with inflammation reduction while soothing the skin. Retinoids, which are vitamin A derivates promote normal skin growth.

In the forecast period, topical calcineurin inhibitors are likely to witness growth, which can be attributed to their low side effect properties. Offering a targeted action, biological therapies are also experiencing traction as an effective treatment alternative.

Netherton Syndrome Market Analysis by Region

Regionally, the market report offers an insight into the United States, EU-4 and the United Kingdom, Germany, France, Italy, Spain, United Kingdom, Japan, and India. The United States, having a robust healthcare infrastructure and a strong presence of prominent biopharmaceutical companies, is estimated to hold a high market value. Increasing collaborations among the key market players boost research initiatives that are expected to fuel the region’s market share.

Asia Pacific is projected to witness substantial growth driven by the improvement in healthcare infrastructure and favorable regulatory environment. Additionally, the rapid growth of the biotechnology sector and increasing investment in genetic research are poised to accelerate the market growth in the region.

Leading Players in the Netherton Syndrome Market

The leading market players are actively engaged in the development and commercialization of promising treatment therapies for Netherton syndrome.

Astellas Pharma Inc.

Astellas Pharma Inc. is a Japanese multinational pharmaceutical company known for its robust portfolio of dermatological products that can be used to treat symptoms associated with Netherton syndrome.

Glenmark Pharmaceuticals

This Indian multinational pharmaceutical company focuses on innovative research and the development of dermatological products such as Pimecrolimus cream, 1%, a prescription medicine used on the skin (topical) to treat mild to moderate eczema.

Allergan, Inc.

This American global pharmaceutical company specializes in medical dermatology, especially in cosmetic and therapeutic skin treatments, which can prove beneficial for managing the skin symptoms associated with Netherton Syndrome.

Dermelix Biotherapeutics

Dermelix Biotherapeutics is a clinical-stage biopharmaceutical company known for its innovative treatments for rare genetic skin diseases. Its genetic therapeutic technologies can deliver medication topically directly to the affected skin area of pediatric patients with Netherton syndrome.

Other players in the market include AbbVie Inc., Reddy's Laboratories Ltd, MatriSys Bioscience, Pfizer Inc., Viatris Inc. (Mylan N.V), Krystal Biotech, Novartis AG, Amneal Pharmaceuticals LLC, Wockhardt, Leo Pharma, Quoin Pharmaceuticals Ltd., Azitra, Inc., and Lifemax Laboratories, Inc.

Several biopharmaceutical companies are recognizing the value of investing in the rare disease market due to various regulatory incentives. Further, the market is witnessing increasing strategic partnerships among the key players to expedite the market entry of viable treatment options for rare disease patients including Netherton Syndrome.

Key Questions Answered in the Netherton Syndrome Market Report

• What was the Netherton syndrome market value in 2023?
• What is the Netherton syndrome market forecast outlook for 2024-2032?
• What are the regional markets covered in the EMR report?
• What is market segmentation based on the route of administration?
• What is the market breakup based on therapy?
• What are the various distribution channels present in the market?
• What are the major factors aiding the Netherton syndrome market demand?
• How has the market performed so far and how is it anticipated to perform in the coming years?
• What are the market's major drivers, opportunities, and restraints?
• Which regional market is expected to lead the market share in the forecast period?
• Which country is expected to experience expedited growth during the forecast period?
• How does the prevalence and incidence of Netherton syndrome affect the market landscape?
• What are the major Netherton syndrome market trends?
• Which disease area will dominate the market share?
• Which route of administration is expected to have a high market value in the coming years?
• Which distribution channel is poised to cover a major market share?
• Who are the key players involved in the rheumatoid arthritis therapeutics market?
• What clinical trials are undergoing in the market?
• How does the regulatory framework impact the market value?
• What is the patent landscape of the market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?

>Meta description

The Netherton Syndrome market size is anticipated to grow at a CAGR of 11.8% during the forecast period of 2024-2032.

*Please Note:* The report will take 7 business days to complete, after order confirmation.